July 19, 2022
Article
Indications for adalimumab include ankylosing spondylitis, Crohn disease, chronic plaque psoriasis, juvenile idiopathic arthritis, moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
July 13, 2022
Some anti-abortion laws may lead to legal action against health care providers who prescribe or provide medications that can be used to induce abortions.
June 22, 2022
Tocilizumab (Actemra) is indicated for treatment of rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
June 17, 2022
Utilization of the RAPID3 tool can be a beneficial way for pharmacists to complete disease activity assessments without physically seeing the patient in a clinic setting.
June 10, 2022
Baricitinib (Olumiant) is indicated for the treatment of rheumatoid arthritis and COVID-19 in hospitalized adults.
June 07, 2022
In addition to the new approval for rheumatoid arthritis, Riabni has already been approved for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.
May 05, 2022
High adherence to treatment is a key first step toward better patient outcomes, including sustained disease control or remission.
March 10, 2022
Insurers, accountable care organizations, and manufacturers increasingly look for demonstrable clinical outcomes as proof for reimbursement or access to limited distribution networks.
March 07, 2022
Amidst the frenzy of blockbuster medicines, the connection between the high price of a drug and how well it works is becoming looser.
March 04, 2022
Upadacitinib (Rinvoq) is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis
